Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules by Sutton, AJ et al.
RESEARCH ARTICLE
Cost-effectiveness of a new autoantibody test
added to Computed Tomography (CT)
compared to CT surveillance alone in the
diagnosis of lung cancer amongst patients
with indeterminate pulmonary nodules
Andrew John SuttonID
1*, Gurdeep S. Sagoo2, Leon Jackson3, Mike Fisher3,
Geoffrey Hamilton-Fairley3, Andrea Murray3, Adam HillID
3,4
1 Institute of Health Economics, Edmonton, Alberta, Canada, 2 Test Evaluation Group, Institute of Health
Sciences, University of Leeds, Leeds, United Kingdom, 3 Oncimmune Limited, City Hospital, Clinical
Sciences Building, Nottingham, United Kingdom, 4 Institute of Global Health Innovation, Imperial College
London, South Kensington Campus, London, United Kingdom
* asutton@ihe.ca
Abstract
Oncimmune’s EarlyCDT®-Lung is a simple ELISA blood test that measures seven lung can-
cer specific autoantibodies and is used in the assessment of malignancy risk in patients with
indeterminate pulmonary nodules (IPNs). The objective of this study was to examine the
cost-effectiveness of EarlyCDT-Lung in the diagnosis of lung cancer amongst patients with
IPNs in addition to CT surveillance, compared to CT surveillance alone which is the current
recommendation by the British Thoracic Society guidelines. A model consisting of a combi-
nation of a decision tree and Markov model was developed using the outcome measure of
the quality adjusted life year (QALY). A life-time time horizon was adopted. The model was
parameterized using a range of secondary sources. At £70 per test, EarlyCDT-Lung and CT
surveillance was found to be cost-effective compared to CT surveillance alone with an incre-
mental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy
parameters used. It was also found that EarlyCDT-Lung can be priced up to £1,177 and still
be cost-effective based on cost-effectiveness acceptance threshold of £20,000 / QALY. Fur-
ther research to resolve parameter uncertainty, was not found to be of value. The results
here demonstrate that at £70 per test the EarlyCDT-Lung will have a positive impact on
patient outcomes and coupled with CT surveillance is a cost-effective approach to the man-
agement of patients with IPNs. The conclusions drawn from this analysis are robust to real-
istic variation in the parameters used in the model.
Introduction
According to Cancer Research UK (https://www.cancerresearchuk.org/health-professional/
cancer-statistics/statistics-by-cancer-type/lung-cancer) there are approximately 50,000 new
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cases of lung cancer every year making lung cancer the third most common cancer in the UK.
Furthermore, lung cancer is the most common cause of cancer death in the UK with 5- and
10-year survival as low as 10% and 5%, respectively (Cancer Research UK), which highlights
the need to detect and correctly treat lung cancer as early as possible. This is particularly perti-
nent when imaging techniques identify indeterminate pulmonary nodules (IPNs) which are
between 4mm and 20mm in size and carry a risk of malignancy of 10–70%. Often this is too
low to justify a biopsy or other invasive procedure that carries a risk of morbidity and accord-
ing to the British Thoracic Society Guidelines [1], an option for the clinician and patient is CT
surveillance or ‘watchful waiting’. This entails repeat scanning at 3 months and 1 year to assess
nodule volume doubling time (VDT). Patients with a VDT below 25% after 1 year are classed
as negative and discharged, though some patients will not be discharged for up to 4 years fol-
low up. Following the introduction of multidetector computed tomography (MDCT), the
number of nodules detected, particularly those that are small, has increased dramatically with
the prevalence of noncalcified lung nodules as 33% (range 17–53%) and 13% (range 2–24%),
in screening and non-screening study populations, respectively [1].
Oncimmune’s EarlyCDT–Lung is a simple ELISA blood test that measures seven lung can-
cer specific autoantibodies, and is used for the assessment of malignancy risk in patients with
IPNs. Robust and easy to use, it can be run in any laboratory with standard laboratory equip-
ment. The test has been marketed in the USA since 2012 and over 150,000 tests have been
sold. A “kit” form of the test was CE marked in May 2017 for distribution to clinical laborato-
ries outside the USA.
Using a decision analytic model, the objective of this study was to examine the cost-effec-
tiveness of autoantibody test (AABT), EarlyCDT–Lung, in the diagnosis of lung cancer
amongst patients with IPNs applied in the addition to CT surveillance, compared to CT sur-
veillance alone as specified in the British Thoracic Society guidelines in which patients are
offered surveillance through repeat CT scanning.
Methods
Developing the model structure
The comparison of the different testing strategies considered in this study are best represented
using a modelling framework in which the various possible testing and treatment pathways can be
compared. The patient group under examination in this study are 62 year old patients [2] with
IPNs. Identified by imaging, these nodules are between 4mm and 20mm in size and carry a risk of
malignancy of 10–65%. A model allows explicit representation of the impact of the accuracy of
the tests, the costs incurred by the health care provider, and the impact on health-related quality
of life (QoL) experienced by the patients that follow a particular diagnostic pathway.
A model which consists of a combination of a decision tree and Markov model was devel-
oped using TreeAge Pro 2001 software (TreeAge Software Inc., Williamstown, MA, USA). A
life-time time horizon was adopted. Given that some events may occur on the patient pathways
many years into the future, a Markov model approach was considered to be most appropriate.
Two different testing pathways were compared which describe alternative approaches to
the testing and surveillance of these patients and their IPNs. The testing pathways are shown
in Fig 1:
Fig 1 shows the testing pathways for the two strategies considered in this analysis. These are
defined as follows:
• AABT+Surveillance–Patients receive the AABT (EarlyCDT-Lung), amongst those that test
positive for malignancy, these are then given a biopsy followed by surgery for those that have
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confirmed malignancy identified through biopsy. Patients that are AABT test negative then
follow the surveillance strategy below and are followed up with CT scans at 3 months, 12
months, and 24 months. Patients that are found to have a nodule that has grown at follow-
up, are given a surgical biopsy. If the nodule is benign no further follow up is required; while
patients that are found to have a malignant nodule receive surgery.
• Surveillance–Patients receive a CT scan at 3 months, 12 months, and 24 months. Those that
test positive for malignancy following a biopsy, are then given surgery for the confirmed
malignancy. Patients that test negative continue on the surveillance pathway. Again, patients
that are found to have a benign nodule that has grown at follow up are given surgical biopsy.
In all cases patients that have surgery are at risk of surgery related mortality and
complications.
Following the approach described by Gould, Sanders [2] Fig 2 shows the model structure
describing the health states of patients and how these evolve over time.
Patients enter the model undiagnosed either with an undiagnosed benign nodule, or an
undiagnosed malignant nodule which may be at a local, regional, or distant stage. Patients that
receive a true positive test then transition to their respective diagnosed state and receive sur-
gery if the nodule is malignant. While those that are false negative (i.e. have a malignant nodule
that is missed) remain undiagnosed but may progress to a more advanced disease state in the
future. Patients that transition to the diagnosed benign state remain in this state under surveil-
lance but may require surgical biopsy in the future if their nodule is subject to significant
growth. Patients in the diagnosed local and regional states are at risk of recurrence or progres-
sion respectively for a period of 5 years after which they are assumed to be disease free. Patients
in the diagnosed distant states are at constant risk of cancer related mortality for the rest of
their lives. In all model states, patients are also subject to all-cause mortality.
Model assumptions
As part of the modelling framework and in order to conduct this analysis it is necessary to
make some assumptions. These are described as follows:
• Biopsy is 100% accurate
• Compliance with surveillance is 100%
• Nodules are diagnosed following a CT scan after doubling/progression
Fig 1. Testing pathways for the AABT and surveillance strategies.
https://doi.org/10.1371/journal.pone.0237492.g001
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• A CT scan is never performed after biopsy or surgery as imaging after an invasive diagnostic
procedure is unusual [2]
• Similarly, biopsy and observation are never performed after surgery [2]
• Surgery will always be performed if biopsy confirms a malignancy [2]
• If biopsy reveals a benign diagnosis, patients are subject to surveillance [2]
• Surgical biopsy is always performed if benign nodule growth is observed during surveillance
[2]
• If no growth is observed after 24 months, then nodule is assumed to be benign and no fur-
ther surveillance is conducted
• CT scans performed during surveillance are 100% accurate at detecting growth in benign
nodules
• Patients in the diagnosed local and regional disease states are at risk of recurrence and pro-
gression for 5 years, after which they are considered to be free from cancer
• Following a positive test, a patient is referred to a multi-disciplinary team (MDT)
Fig 2. Markov model (reproduced from Gould, Sanders [2]).
https://doi.org/10.1371/journal.pone.0237492.g002
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Data requirements
The data required to parameterise the economic model were obtained through the extensive
use of secondary sources. The parameters used in this model can be broadly categorized into
prevalence of malignancy, accuracy parameters, transition probabilities between model states,
resource use and costs, and utility values.
Prevalence
In the base case scenario, the prevalence of malignancy amongst patients presenting with IPNs
was taken to be 9.5% (7/74) which is applied to both arms of the analysis. This is based on the
logic as described by Edelsberg, Weycker [3] to interpret the data described in the study by
Tanner, Porter [4], which is as follows:
In the study by Tanner, 74 patients were assigned to CT surveillance from an intermediate-
risk group, amongst which 7 had lung cancer, yielding a lung cancer prevalence of 9.5 (7/74).
Test accuracy
Two alternative scenarios which describe the test accuracy of the AABT test are considered in this
analysis, which are based on the availability of current test accuracy parameters for the AABT.
The test accuracy parameters for the tests considered in this analysis are described Table 1 below:
The data from the 12 studies used in Gould, Sanders [2] to estimate the test accuracy values
for a CT scan were re-analysed using the Metandi function in Stata so that the necessary infor-
mation for the probabilistic sensitivity analysis could be obtained (see below). This led to
slightly different sensitivity and specificity values compared to those reported by Gould, Sand-
ers [2] (Gould values: Sensitivity = 0.965; specificity = 0.558).
Transition probabilities
Table 2 describes the probabilities and proportions that are applied to the economic model. In
all cases, unless otherwise noted, the probabilities are monthly probabilities.
Calculation of cancer related mortality rates
Mortality rates for patients in the local, regional, and distant cancer states post-surgery were
calculated by fitting a model by maximum likelihood to data survival curves for patients with
pathologically staged lung cancer (T1N0M0), pathologically staged regional lung cancer (any
T N1–3 M0), and distant lung cancer (any T any N M1) from the linked Medicare claims–Sur-
veillance, Epidemiology and End Results (SEER) tumour registry, US [2].
Local cancer-related mortality was derived from survival data for 1,207 Medicare beneficia-
ries with surgically treated, T1N0M0 non–small-cell lung cancer. The regional cancer-related
mortality was derived from survival data for 1954 Medicare beneficiaries with pathologically
staged regional lung cancer. The distant cancer-related mortality was estimated from 10 835
Medicare beneficiaries with distant-stage non-small-cell lung cancer. All data here are from
the SEER tumour registry, 1990–1993, as described in Gould, Sanders [2] (Fig 3).
Table 1. Test accuracy parameter values.
Test Sensitivity Specificity Reference
AABT:
Scenario A 0.41 0.93 Taken from a ROC curve described in [5]
Scenario B 0.28 0.98 “”
CT Scan 0.923 0.723 [2] (taken from a meta-analysis of 12 studies)
https://doi.org/10.1371/journal.pone.0237492.t001
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Table 2. Transition probabilities used in the model.
Parameter Value Reference
Proportion of malignant nodules that are
initially:
Local Stage 0.875 [2]
Regional Stage 0.125 (0.078–
0.165)
“”
Probability of detecting growth in a benign
nodule during observation period: During first
month
0.28 (0.13–0.29) [2]
During each subsequent month 0.005 (0–0.01) [2]
Natural Mortality Varied by age Office of National Statistics (2018)
Probability distant cancer related mortality [2] (use+-50% as Gould)
0–12 months 0.1255 (+-50%
Gould)
13–24 months 0.0670 (+-50%
Gould)
25–36 months 0.0589 (+-50%
Gould)
37–48 months 0.0150 (+-50%
Gould)
Mortality Undiagnosed malignant nodule 0.02688 (+-50%
Gould)
Based on a life expectancy of 36.7 months for
patient with untreated 2cm nodule that
doubled every 5.24 months [2]
Probability of progression from undiagnosed
local to regional, and from undiagnosed
regional to distant cancer
0.19224 (0.18887–
0.21005; 95% CI)
[2]
Probability mortality due to biopsy 29/31960 [6]
Probability guided needle biopsy
complications
230/31960 “”
Probability mortality due to recurrence Calculated from data. See text [2]
0–12 months 0.0106 (use +-50% see Gould)
13–24 months 0.0100
25–36 months 0.0090
37–48 months 0.0114
Probability mortality due regional cancer “”
0–12 months 0.0340 (use +-50% see Gould)
13–24 months 0.0296
25–36 months 0.0225
37–48 months 0.0155
Surgery related mortality for malignant nodule 0.042 (0.017–
0.053)
[2]
Surgery related mortality for benign nodule 0.005 (0.002–
0.016)
“”
Surgery complications for malignant nodules 0.084 (0.048–
0.11)
[2]
Surgery complications for benign nodules 0.065 (0.033–
0.13)
“”
Proportion of patients that receive
radiotherapy with surgery
5/35 [7]
Proportion of patients that receive
chemotherapy with surgery
11/35 “”
https://doi.org/10.1371/journal.pone.0237492.t002
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Calculation of cancer progression rates
To calculate the progression rates amongst patients with undiagnosed malignant nodules, the
observed doubling times in the figure above were used. A model (probability of progression =
1-exp(-rate�t)) to obtain the monthly probability of progression was fit to the data (Fig 4)
using maximum likelihood. The resulting model output showing 1 –probability of progression
over time is also shown in Fig 4.
Costs and resource use
Table 3 describes the costs applied in the economic model. All costs are in pounds (£)
sterling for the 2016/17 price year. NHS Reference costs were used to attribute costs to
resource use.
Fig 3. Survival curves for patients with pathologically staged local lung cancer (T1N0M0), pathologically staged
regional lung cancer (any T N1-3 M0) and distant lung cancer (any T any N M1) from the linked Medicare
claims–Surveillance, Epidemiology and End Results (SEER) tumour registry, USA. (Reproduced from Gould,
Sanders [2]).
https://doi.org/10.1371/journal.pone.0237492.g003
Fig 4. The frequency plot of the observed doubling times for 67 pulmonary nodules and mass lesions from the
veterans administration–armed forces cooperative study on asymptomatic pulmonary nodules (described in
Gould, Sanders [2]). Dashed line shows model output to estimate monthly progression rate.
https://doi.org/10.1371/journal.pone.0237492.g004
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Utility values
The utility values used in the analysis to inform the quality adjusted life year (QALY) are
described in Table 4 below.
Analysis
This model-based economic evaluation utilizes the primary outcome of the cost per QALY,
where one QALY is defined as one year lived in perfect health. A time step of 1 month was
applied in the Markov model with a life-time time horizon. This time horizon was chosen to
allow the full impact of the interventions that may occur many years in the future to be
included. Half cycle correction was incorporated into the analysis. Discounting was applied at
3.5% for costs and outcomes as recommended by NICE [10], with the analysis conducted from
the health-care provider perspective The results are presented using the incremental cost-effec-
tiveness ratio (ICER) which is defined as the difference in the costs of the two strategies divided
by the difference in their outcomes, and net-monetary benefit (NMB) which is defined for
each strategy as:
NMB ¼ QALYs gained x willingness to pay ðWTPÞ for a QALY   Cost of the intervention:
Where the WTP for the QALY is taken to be £20,000, which is at the lower end of the £20,000
to £30,000 acceptance threshold as recommended by NICE [10].
Table 3. Resource use unit costs.
Parameter Value Reference (NHS Reference Costs 2016/17 unless otherwise noted)
AABT £70 Oncimmune
CT Scan (single area, no contrast) £85.56 RD20A - Computerised Tomography Scan of One Area, without Contrast, 19 years and over
MDT (Multidisciplinary team) £111.99 CMDT_Oth
Guided Needle biopsy £948.92 DZ71Z Minor Thoracic Procedures
Surgery no complications £7,713.03 DZ02K Complex Thoracic Procedures, 19 years and over, with CC Score 0–2
Surgery + complications £10,177.74 DZ02H Complex Thoracic Procedures, 19 years and over, with CC Score 6+
Surgery: biopsy no complications £3,091.08 DZ63C Major Thoracic Procedures, 19 years and over, with CC Score 0–2
Surgery: biopsy with complications £6,733.76 DZ63A Major Thoracic Procedures, 19 years and over, with CC Score 6+
Radiotherapy £3,252 [7], inflated from 2011/12 prices (£3,039)
Chemotherapy £4,155.15 [7], inflated from 2011/12 prices (£3,883)
https://doi.org/10.1371/journal.pone.0237492.t003
Table 4. Utility values.
Parameter Value Reference
Age 55–64 0.810 [8] EQ-5D index value population norms for the UK–England, using country
specific Time-trade off (TTO) values
Age 65–74 0.773 “”
Age 75+ 0.703 “”
Serious adverse event due
to biopsy
-0.2 [6]
Local 0.71 n = 33 (stage IA and IB) at 12 months [9]
Regional 0.65 n = 12 (stage I and Stage II) at 12 months “”
Distant 0.62 n = 4 (stage IV) at 12 months “”
https://doi.org/10.1371/journal.pone.0237492.t004
PLOS ONE New autoantibody test vs. CT surveillance for diagnosis of lung cancer for patients with IPNs
PLOS ONE | https://doi.org/10.1371/journal.pone.0237492 September 2, 2020 8 / 16
Sensitivity analysis
This analysis contains a number of important uncertainties that must be examined. These
were examined through one-way and probabilistic sensitivity analyses.
Given this is an early economic evaluation the optimum price of the AABT test is examined.
The price of the AABT test was varied to show the point at which the price of the test leads to
an ICER of £20,000/QALY which is at the low end of the threshold for acceptance of an inter-
vention as given by NICE [10].
Probabilistic sensitivity analysis (PSA) was implemented by using Beta distributions where
data made this possible, using the method of moments to obtain the Alpha and Beta parame-
ters in each case [11]. Where a range was described for parameter uncertainty, then the stan-
dard error for the Beta distribution was estimated as follows:
SE ¼ ðU  LÞ=ð2� 1:96Þ
Where U and L are the upper and lower limits of the range respectively [12].
In order to apply probabilistic sensitivity analysis (PSA) to the CT scan test accuracy values
the following equation was used
logit sensitivityð Þ ¼ Le 
b
2   e  blogit specificityð Þ
From the metandi output in Stata (see Test Accuracy Section above), specificity was 0.7234
(se = 0.0276), Λ was found to be 3.156 (se = 0.2296) and β = -0.5362433. The resulting sensitiv-
ity was estimated by sampling from a beta distribution for the specificity and sampling from a
normal distribution for Λ. Beta was kept constant.
Expected value of perfect information
The expected value of perfect information (EVPI) is based on the probability of a decision
maker making the wrong decision about which testing strategy to choose and the impact of
making that wrong decision. It provides insights into the maximum value of conducting fur-
ther research to resolve the uncertainty in the parameter values. Expected value of perfect
parameter information (EVPPI) takes this idea forward and shows the maximum value of
resolving the uncertainty in specific parameters or specific groups of parameters. Both meth-
ods are useful in providing insights into the direction of future research. The methods used
here to estimate the EVPI and EVPPI are those described by Strong, Oakley [13].
Results
The results here are presented for two scenarios based on alternative estimates for the test
accuracy of the AABT test (Scenario A–Sensitivity 0.41 Specificity 0.93; Scenario B–Sensitivity
0.28 Specificity 0.98).
Scenario A
At a price of £70, the cost-effectiveness results for AABT vs Surveillance for Scenario A show-
ing the average cost and QALYs gained per patient are shown in Table 5 below:
Table 5. Cost-effectiveness of AABT vs. surveillance for testing Scenario A, where the price of AABT = £70.
Scenario A:
Total Cost Inc. Cost QALYs Gained Inc. QALYs ICER (Cost/QALY)
Surveillance £2,261 10.6850
AABT+Surveillance £2,410 £149 10.7465 0.0614 £2,417
https://doi.org/10.1371/journal.pone.0237492.t005
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It can be seen that when the price for AABT = £70, and adopting the test accuracy parame-
ters as described for Scenario A, AABT+Surveillance is more costly and more effective in
terms of QALYs gained than surveillance alone. Given that the ICER is well under £20,000,
AABT+Surveillance can certainly be regarded as cost-effective.
The results when the uncertainty in the parameter values is considered in the analysis for
Scenario A are shown in Fig 5 above. It can be seen that AABT+Surveillance is always more
costly than surveillance alone and almost always (99.4%) more effective in terms of QALYs
gained. The cost-effectiveness acceptability curve (CEAC) shows that AABT+Surveillance is
more likely to be cost-effective at a WTP for the QALY of £2,000 and above. At a WTP of
£20,000/QALY AABT is approximately 99% likely to be cost-effective.
The net benefit for the AABT+Surveillance and Surveillance alone scenarios with variation
in the price of the AABT test for Scenario A are shown in Fig 6.
It can be seen that the price of the AABT can be up to £1,150.37 and still have greater NMB
than compared to Surveillance alone (WTP = £20,000). Above this price, surveillance alone
becomes more cost-effective.
Assuming an annual incidence of 50,000 patients presenting with IPNs, a discount rate of
3.5% and a 10-year time horizon after which this technology will be superseded, the expected
value of information for Scenario A is shown in the figure below.
Fig 5. Probabilistic sensitivity analysis results for Scenario A for 1,000 model runs showing the cost-effectiveness
plane and the cost-effectiveness acceptability curve for Scenario A.
https://doi.org/10.1371/journal.pone.0237492.g005
Fig 6. Net monetary benefit at a WTP = £20,000 / QALY for the AABT+Surveillance and surveillance strategies
with variation in the price of the AABT test for Scenario A.
https://doi.org/10.1371/journal.pone.0237492.g006
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It can be seen in Fig 7 that at a WTP for the QALY of £20,000, the EVPI for Scenario A is
approximately £1,000,000.
In terms of expected value of perfect parameter information. The EVPPI for different
groups of parameters for Scenario A are shown in Fig 8 below.
It can be seen (Fig 8) that there is some value in resolving the uncertainty in the disease
related mortality rates, initial patient characteristics (i.e. prevalence and proportion of patients
with local and regional disease) and the utility values. The most value of resolving this uncer-
tainty over 10 years is achieved by targeting the mortality rates (approximately £600,000),
while the values for the other parameters is actually very low being approximately £80,000 for
the initial patient characteristics and £25,000 for the utility values.
Scenario B
Similar to Scenario A, when the price for AABT = £70, and adopting the test accuracy parame-
ters as described for Scenario B, AABT+Surveillance is more costly and more effective in
Fig 7. Expected value of information for Scenario A. Assuming an incidence of 50,000 new patients presenting with
IPNs, a discount rate of 3.5% and a 10-year time horizon.
https://doi.org/10.1371/journal.pone.0237492.g007
Fig 8. Expected value of perfect parameter information for Scenario A.
https://doi.org/10.1371/journal.pone.0237492.g008
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terms of QALYs gained than Surveillance alone. Again, given the low ICER value, AABT can
certainly be regarded as cost-effective (Table 6).
It can be seen from the results of the PSA for Scenario B (Fig 9) that AABT+Surveillance is
always more costly than surveillance alone and always more effective in terms of QALYs
gained. The cost-effectiveness acceptability curve (CEAC) shows that AABT+Surveillance is
more likely to be cost-effective at a WTP for the QALY of £3,000 and above. At a WTP of
£20,000/QALY AABT is more than 98% likely to be cost-effective.
The net benefit for the AABT+Surveillance and Surveillance scenarios with variation in the
price of the AABT test for Scenario B are shown in Fig 10.
In the case of the test accuracy parameters in scenario B the AABT test can be priced up to
£887.28, and be more cost-effective than surveillance alone (WTP = £20,000/QALY).
It can be seen in Fig 11 that at a WTP for the QALY of £20,000 the EVPI for Scenario B is
approximately £100,000. In the case of Scenario B, there was found to be no value in resolving
the uncertainty in any of the parameter groups (not shown).
Analysis of Scenario A and Scenario B
Given that both Scenarios A and B show that AABT+Surveillance is cost effective compared to
surveillance alone, it is important to establish whether the extra QALYs gained from Scenario
A compared to Scenario B are worth paying for.
As shown in Table 7, the ICER for AABT+Surveillance Scenario A compared to Scenario B
is £3,277 which is well below the NICE acceptance threshold of £20,000. Thus, it can be con-
cluded that Scenario A has the most cost-effective test accuracy parameters and as such these
should be adopted.
The CEAC for the 3 scenarios is shown below:
It can be seen from the CEAC shown in Fig 12 that up to a WTP for a QALY of approxi-
mately £2,000, Surveillance alone is most likely to be the most cost-effective scenario, and then
from WTP of approximately £3,000 upwards AABT+Surveillance Scenario A is most likely to
be cost-effective. At a WTP for a QALY of £20,000 Scenario A is approximately 90% likely to
be the most cost-effective option, with this probability increasing with increased WTP values.
Table 6. Cost-effectiveness of AABT+Surveillance vs. surveillance alone for testing Scenario B, where the price of AABT = £70.
Scenario B:
Total Cost Inc. Cost QALYs Gained Inc. QALYs ICER (Cost/QALY)
Surveillance £2,261 10.6850
AABT+Surveillance £2,358 £97 10.7308 0.0457 £2,121
https://doi.org/10.1371/journal.pone.0237492.t006
Fig 9. Probabilistic sensitivity analysis results for Scenario B for 1,000 model runs showing the cost-effectiveness
plane and the cost-effectiveness acceptability curve for Scenario B.
https://doi.org/10.1371/journal.pone.0237492.g009
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Discussion
Using a decision modelling framework consisting of a decision tree and Markov model the
analysis here has examined the cost-effectiveness of the AABT test in addition to CT surveil-
lance compared to the current practice of CT surveillance alone for patients with indetermi-
nate pulmonary nodules (IPNs), as recommended in the British Thoracic Society guidelines.
Two alternative pairs of test accuracy parameters were considered for the AABT test. Scenario
A (sensitivity 41% specificity 93%) with its higher sensitivity and lower specificity compared to
Scenario B (sensitivity 28% Specificity 98%). This analysis took a baseline price of the AABT
test to be £70, but also investigated the maximum price the test could be set at, and still remain
cost-effective at these values.
Based on the results of this analysis at baseline, it is quite clear that the use of the AABT test
in addition to CT surveillance is cost-effective compared to CT surveillance alone. And while
Fig 10. Net monetary benefit at a WTP = £20,000 / QALY for the AABT+Surveillance and surveillance alone
strategies with variation in the price of the AABT test for Scenario B.
https://doi.org/10.1371/journal.pone.0237492.g010
Fig 11. Expected value of information for Scenario B. Assuming an incidence of 50,000 new patients presenting with
IPNs, a discount rate of 3.5% and a 10-year time horizon.
https://doi.org/10.1371/journal.pone.0237492.g011
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at £70 per test, the test was never found to be cost saving, based on the NICE threshold of
acceptance (i.e. less than £20,000 / QALY) the extra effect in terms of QALYs was always
found to be worth paying for. In terms of which test accuracy parameters should be adopted,
again the results here are clear, with Scenario A (Sensitivity 41% Specificity 93%) being the pre-
ferred option. The probabilistic sensitivity analysis supports the main conclusions and indeed
provide reassurance that these results are robust to realistic variations in the input parameters.
Thus, it can be concluded that the extra sensitivity of Scenario A compared to Scenario B (41%
vs. 28%) at the expense of some specificity (93% vs. 98%) leads to improved patient outcomes
that are worth paying for.
The results here also demonstrate that at £70, the AABT test is significantly under-priced
and could be priced at between approximately £900 to £1,170 (depending on the Scenario) and
still be cost-effective based on the NICE acceptance threshold for the QALY. Although it is
acknowledged that while this would still be under the NICE acceptance threshold, the
increased budget impact would obviously make this much less attractive to decision makers.
“The intuition behind the results here is that by adding the additional AABT diagnostic test
to current surveillance, there is a positive trade off between the patient benefits associated with
the detection of true positives and the negative impact of a slight increase in the number of
false positive test results due to imperfect specificity that will lead to a further biopsy. However,
given the very high specificity of the AABT test and the relatively high prevalence of malig-
nancy (approx. 10%), there is very little downside to a patient receiving this test, apart from
the cost of the test. If a patient is found to require surgery as a result of a true positive test, then
this clearly has a positive impact on patient outcomes, while a false negative test simply leads
the patient to the surveillance test pathway, which is what the patient would have received in
the absence of the AABT test. Even though it could be argued that the sensitivity is still
Table 7. Cost-effectiveness results showing a comparison between Surveillance and AABT for Scenarios A and B.
Total Cost Inc. Cost QALYs Gained Inc. QALYs ICER (Cost/QALY)
Surveillance £2,261 10.6850
AABT+Surveillance Scenario B £2,358 £97 10.7308 0.0457 £2,121.43
AABT+Surveillance Scenario A £2,410 £52 10.7465 0.0157 £3,277.41
https://doi.org/10.1371/journal.pone.0237492.t007
Fig 12. Cost-effectiveness acceptability curve comparing surveillance, AABT+Surveillance Scenario A, and AABT
+Surveillance Scenario B.
https://doi.org/10.1371/journal.pone.0237492.g012
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relatively low (41% is the highest in Scenario A), this is still sufficient to have a positive impact
on patient outcomes.”
The conclusions drawn from this analysis are supported in the study by Edelsberg, Weycker
[3] which also found the AABT test in addition to CT surveillance to be cost-effective com-
pared to surveillance alone. However, our analysis differs from the approach taken by these
authors in that we use a Markov model which allows for patients to be followed over their life-
time. While Edelsberg, Weycker [3] do attempt to draw conclusions over longer time horizons,
the Markov model is regarded as the most appropriate model design for chronic diseases.
This analysis has a number of limitations that have to be acknowledged. The cost of pallia-
tive care for patients that die of lung cancer have not been incorporated into this analysis.
However, given that patient outcomes are improved in the AABT plus surveillance scenario,
their inclusion would cause the AABT to appear even more cost-effective than has been pre-
sented in these results. Rather than doing an extensive systematic review to identify the best
available evidence to populate the model, this study has made extensive use of the parameters,
data and model structure from the study by [2]. While this should be regarded as a limitation,
the uncertainty in the parameter values used has have been subject to extensive sensitivity anal-
ysis and this has shown that the conclusions drawn from this analysis are robust to realistic
variation in the parameter values.
Conclusion
The results here have demonstrated that the use of the EarlyCDT–Lung AABT test in addition
to CT surveillance will have a positive impact on patient outcomes and is a cost-effective
approach to the management of patients with IPNs, with all the results well under the NICE
threshold for acceptance. The conclusions drawn from this analysis are also very robust to real-
istic variation in the parameters used in this model.
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